• 1
    Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 24552.
  • 2
    Palucka K, Banchereau J. Dendritic cells: a link between innate and adaptive immunity. J Clin Immunol 1999; 19: 1225.
  • 3
    Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expresion on NKT cells. J Exp Med 1999; 189: 11218.
  • 4
    Ridge JP, Rosa FD, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 4748.
  • 5
    Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001; 95: 45973.
  • 6
    Thuener B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuleret G. Vaccination with MAGE-3A1 peptide-pulsed mature, monocytes-derived dendritic cells expands specific cytotoxic T calls and induces regression of some metastasis in advanced stage IV melanoma. J Exp Med 1999; 190: 166978.
  • 7
    Lee K, Wang E, Nielsen M, Wunderrilich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999; 163: 6292300.
  • 8
    Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18: 24573.
  • 9
    Bennett SR, Carbone FR, Karamalis F, Fravell RA, Miller JFAP, Heath WR. Help for cytotoxic T cell responses is mediated by CD40 signaling. Nature 1998; 393: 47880.
  • 10
    Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 4803.
  • 11
    Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 1999; 182: 8219.
  • 12
    Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, Salvato P, Thompson C, Loveless M, Shapiro DE, Elsasser W. A controlled clinical trial with a specifically configured RNA drug, poly(I):poly(C) 12 U, in chronic fatigue syndrome. Clin Infect Dis 1994; 18: S8895.
  • 13
    Reddy A, Sapp M, Feldman M, Subklewe M, Bhardwaj N. A monocytes conditioned medium is more effective than defined cytokines mediating the terminal maturation of human dendritic cells. Blood 1997; 90: 36406.
  • 14
    Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immuno-stimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27: 313542.
  • 15
    Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res 2003; 63: 41128.
  • 16
    Okamoto H, Shin J, Mion S, Koshimura S, Shimizu R. Studies on the anti-cancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 1967; 11: 32336.
  • 17
    Thurner B, Roder C, Dickmann D, Heuer M, Kruse M, Slaser A, Keikavoussi P, Kampgen E, Bender A, Schuler G. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical apprication. J Immunol Methods 1999; 223: 115.
  • 18
    Feuerstein B, Berger TG, Maczek C, Roder C, Schreiner D, Hirsch U, Haendle I, Leisgang W, Glaser A, Kuss O, Diegen TL, Schuler G, Schuler-Thurner B. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J Immunol Methods 2000; 245: 1529.
  • 19
    Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibi B, Niederwieser D, Schuler G. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996; 196: 13751.
  • 20
    Hirao M, Onai N, Hiroishi K, Watkins SC, Matsushima K, Robbins PD, Lotze MT, Tahara H. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptopic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 2000; 60: 220917.
  • 21
    Luft T, Jefford M, Luetjens P, Toy T, Hochrei H, Masterman KA, Maliszewski C, Shortman K, Cebon J, Maraskovsky E. Functional distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets. Blood 2002; 100: 136272.
  • 22
    Scandella E, Men Y, Gillessen S, Forster R, Groettrup M. Pristaglandin E2 is a key factor CCR7 surface expression and migration of monocytes-derived dendritic cells. Blood 2002; 100: 135461.
  • 23
    Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000; 60: 82933.
  • 24
    Murphy GP, Tojoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase 2 prostate cancer vaccine trail involving patients with hormone-refractory metastatic disease. Prostate 1999; 38: 738.
  • 25
    Dhodapkar MV, Steinmen RM, Krasovsky J, Munz M, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 2338.
  • 26
    Toyokawa H, Inaba M, Takai S, Satoi S, Beuth J, Ko HL, Matsui Y, Kwon AH, Kamiyama Y, Ikehara S. Enhancement of circulating dendritic cell activity by immunomodulators (OK-432 and KP-40). Anticancer Res 2002; 22: 213745.
  • 27
    Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+ CD25+ T cell-mediated suppression by dendritic cells. Science 2003; 299: 10336.
  • 28
    Forster R, Schubel A, Brerifeld D, Kremmer E, Renner-Muller I, Wolf E, Lipp M. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999; 99: 2333.
  • 29
    Cyster JG. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 1999; 189: 44750.
  • 30
    Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Ait-Yahia S, Briere F, Zlotnik A, Lebecque S, Caux C. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic site. J Exp Med 1998; 188: 37386.
  • 31
    Sallusto F, Palermo B, Lenig D, Mittinen M, Matikainen S, Julkunen I, Forster R, Burgstahler R, Lipp M, Lanzavecchia A. Distinct pattern and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 1999; 29: 161725.
  • 32
    Yanagihara S, Komura E, Nagafue J, Watarai H, Yamaguchi Y. ERI1/CCR7 is new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J Immunol 1998; 161: 3096102.
  • 33
    Kalinski P, Vieria PL, Schuitemaker JH, de Jong EC, Kapsenberg ML. Prostaglandin E2 is a selective inducer of interleukin-12p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001; 97: 344649.
  • 34
    Steinbrink K, Paragnik L, Jonuleit H, Tuting T, Knop J, Enk AH. Induction of dendritic cell maturation and modulation of dendritic cell-induced immune responses by prostaglandins. Arch Dermatol Res 2000; 292: 43745.